Clinical Trial Update: Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing gemcitabine with vs without exatecan mesylate in locally advanced or metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Exatecan Mesylate (exatecan mesylate)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED